

18th Annual

# PERSPECTIVES IN UROLOGY POINT COUNTERPOINT 2009

November 5–7, 2009 • The Scottsdale Plaza • Scottsdale, Arizona

*Course Director: E. David Crawford, MD*

*Faculty: David C. Beyer, MD, FACR, FACRO, FASTRO Robert E. Donohue, MD*

*Brian J. Flynn, MD • Donald L. Lamm, MD*

*M. Scott Lucia, MD • Paul D. Maroni, MD*

*Mark A. Moyad, MD, MPH • Jacob Rajfer, MD*

*Matthew Rettig, MD*

*Sponsored by*

**GRANT/DOWNING**  
E D U C A T I O N

*The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of the commercial supporters, any other manufacturer of pharmaceuticals, or Grant/Downing, LLC.*

*The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any presented in this activity for recommended dosage, indications, contraindications, warnings, precautions and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently used.*

© 2009

*All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Grant/Downing, LLC.*

**Table of Contents**

Program Information ..... 4  
Course Director and Faculty Biographies ..... 6  
Disclosures ..... 13  
Agenda..... 14



## Introduction

This program has been designed to address key questions on potentially practice changing developments in the field of urology and to provide urologists, trainees, and other health care professionals involved in the diagnosis and management of urology diseases with the framework to integrate these developments into their daily practice. These educational offerings are designed to enhance patient assessment and outcomes, and will include didactic lectures, debates, case presentations, and question and answer sessions.

## Objectives

*After completing this activity, participants will demonstrate:*

1. Improved management of patients with 'castration-resistant prostate cancer,' based on a strong knowledge base that includes current studies on role of PSA doubling time, testosterone level, and outcomes with newer vs older pharmacologic agents
2. Differentiation of fact from fiction regarding frequency of use and outcomes of robotic vs open radical prostatectomy across multiple parameters: continence, potency, cancer recurrence, PSA levels, positive margin rates, cost and experience of the surgeon
3. Evidence-based clinical decision-making regarding evaluation and treatment of androgen deficiency syndromes, based on updated data regarding diagnostic assays of testosterone, contraindications to testosterone replacement therapy (TRT), evidence of multisystem TRT benefits, and distinctive properties of diverse formulations
4. Informed resolution of concerns that impact use of TRT in aging men with symptomatic hypogonadism, with consequent benefit to untreated patients who are appropriate candidates for TRT
5. Evaluation and management of men aged >50 with these clinically documented data in mind: underdiagnosis and undertreatment of enlarged prostate and attendant lower urinary tract symptoms; predictive value of PSA for risk of enlarged prostate (EP) progression; goal of treatment to include prevention of acute urinary retention (AUR) and EP-associated surgery; documented efficacy of single and combined therapies
6. Clinical decision-making consistent with the 2009 AUA Updated Guideline for Clinical Stage 1 Renal Mass with particular focus on the significance of current histologic subtyping, consideration of tumor volume and evolving molecular markers, the diversity of treatment modalities both standard and novel, and definition of the patient population for whom active surveillance is a reasonable option
7. Treatment selection for bladder cancer based on thorough understanding of risk stratification and appropriate use of BCG to prevent treatment failures, as well as awareness of clinical data on therapeutic options post-BCG failure
8. Informed judgments on the role of radiation therapy in select populations with bladder cancer
9. Improvement in outcomes for surgical stress incontinence procedures, based on comprehensive knowledge of optional approaches and caveats for specific procedures, e.g., effective materials for transvaginal tape in pubovaginal sling procedure, predictors of voiding dysfunction post-pubovaginal sling, techniques for minimally invasive prolapse surgery, management of apical vaginal defect
10. Inclusion of complementary alternative strategies where appropriate, including chemoprevention and early treatment of prostate cancer as well as BPH, mindful of updated data analyses, e.g., cardioprotective and prostate-protective parallels; conflict regarding finasteride; role of antioxidants and vitamin D; problems with excessive supplementation

**Continuing  
Education  
Credit**

**GRANT/DOWNING  
E D U C A T I O N**



Grant/Downing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Grant/Downing Education designates this educational activity for a maximum of *15.25 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in this activity.

**Acknowledgement**

"Perspectives in Urology: Point Counterpoint" is supported in part by unrestricted educational grants and exhibit fees from **Abbott Laboratories**, **AstraZeneca**, **Audio-Digest Foundation**, **Cook Urological**, **Dendreon Corporation**, **Endo Pharmaceuticals**, **Ferring Pharmaceuticals**, **Genentech**, **Novartis**, **Olympus**, **Onco Diagnostics**, **Solvay Pharmaceuticals**, and **Watson Pharma, Inc.**

## Course Director

### **E. David Crawford, MD**

*Professor of Surgery/Urology/Radiation Oncology  
Head, Urologic Oncology  
E. David Crawford Endowed Chair in Urologic Oncology  
University of Colorado, Denver*

E. David Crawford is the E. David Crawford distinguished professor of surgery, urology, and radiation oncology, and head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center (UCHSC) in Denver. He serves as the senior associate director of the University of Colorado Comprehensive Cancer Center, also in Denver.

Dr Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship with Dr Donald G. Skinner at the University of California Medical Center in Los Angeles.

Dr Crawford is a nationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 450 articles that have been published in such journals as *Urology*, *The New England Journal of Medicine*, *the Journal of Urology*, and the *Journal of the National Cancer Institute*. He has published five textbooks and authored over 50 book chapters, and is an editorial reviewer or consultant for a large number of publications, including *Urology*, *Journal of Urology*, *The New England Journal of Medicine*, *Cancer*, and the *Journal of Clinical Oncology*.

Dr Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he was a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and chairs the National Prostate Cancer Education Council. His involvement in the national prostate cancer arena has been widely recognized. Dr Crawford has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a "Freddie Award" at the AMA International Health and Medical Film Competition for the program *ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating)*, which Dr Crawford hosted with special guest retired General Norman Schwarzkopf. He again won a prestigious "Freddie Award" in 2005. He has been recognized as one of the Best Doctors of America for the past decade, and one of the Best Cancer Doctors. In 2007 he was awarded the honor of being selected as the Best Healthcare Provider in the Denver Metro area by the Denver Business Journal, Blue Cross, and Anthem Healthcare. In 2007, he was recognized as one of the top 20 Urologists in the country for men by Men's Health Magazine.

## Faculty

### **David C. Beyer, MD, FACR, FACRO, FASTRO**

*Arizona Oncology Services  
Scottsdale, Arizona*

David C. Beyer, MD, FACR, FACRO, FASTRO is Vice President of Arizona Oncology Services, Inc. He serves as Vice Chair of the Health Policy Council on the Board for the American Society of Therapeutic Radiology & Oncology (ASTRO), is on the Board of Chancellors with the American College of Radiation Oncology (ACRO), and is an Editorial Board Member of the *Journal of Brachytherapy*.

Dr Beyer earned his medical degree from the University of Arizona, College of Medicine after completing a degree in electrical engineering from Massachusetts Institute of Technology. He joined Arizona Oncology Services in 1985, after serving consecutive residencies in both internal medicine and radiation oncology at the University of Arizona Health Sciences Center and University of California, Los Angeles. He is a member of Alpha Omega Alpha Honorary Society. Dr Beyer is a Fellow of the American College of Radiation Oncology (ACRO), the American College of Radiology (ACR), and the American Society for Therapeutic Radiology and Oncology.

Dr Beyer's primary clinical interests focus on prostate cancer and prostate Brachytherapy, including seed implants, and high dose rate (HDR) Brachytherapy. He has comprehensive experience in intensity modulated radiation therapy (IMRT) and image guidance radiation therapy (IGRT). He is a frequent lecturer at implant training courses and medical meetings, and has published extensively the Arizona Oncology Services results in prostate treatment.

Dr Beyer is board certified with the American Board of Radiology, the American Board of Internal Medicine, and Therapeutic Radiology.

---

### **Robert E. Donohue, MD**

*Professor of Surgery/Urology  
University of Colorado Health Sciences Center  
Chief of Urology  
Veterans Administration Medical Center*

Robert E. "Bob" Donohue graduated from New York University School of Medicine in 1964. After medical school, Dr Donohue completed a general surgery internship at Bellevue Hospital in New York. Dr Donohue completed his urology residency at New York University Medical Center in 1970. After completing his residency training, Dr Donohue continued his surgical training as a Valentine Fellow at the New York Academy of Medicine at Memorial Hospital for Cancer and Allied Diseases (1970-1971) and as a Senior Registrar in Urology at Christchurch Hospital affiliated with the University of Otago Medical School in New Zealand.

Dr Donohue received his certification from the American Board of Urology in 1974. He joined the faculty of the University of Colorado School of Medicine as Assistant Professor of Surgery/Urology in 1972. Dr Donohue was promoted to the rank of Associate Professor at the CU School of Medicine in 1978, and was promoted to the rank of Professor in 1992. In 1977, Dr Donohue was appointed Chief of Urology at the Denver Veterans Administration Medical Center and continues to hold that appointment. Dr Donohue served as the Acting Chief of Surgical Services at the Denver VAMC from 1982 to 1984. From 1989 to the present, Dr Donohue has served as the Chairman of the Cancer Committee and the Director of the Tumor Board at the Denver VA Medical Center. *(continued...)*

## Faculty

*Robert E. Donohue, MD (continued)*

Dr Donohue has published and presented on wide variety of topics, and from 1989 to 1994, he was the Associate Editor of the *Journal of Urology*. Dr Donohue's research interests include Hox gene expression in the prostate, polymorphism of vitamin D receptor genes, screening for prostate, lung, colo-rectal, and ovarian cancers, and treatment for benign prostatic hyperplasia. Dr Donohue's practice encompasses most areas of general urology with special interest in benign testicular masses, impalpable testicular lesions, paratesticular masses (benign and malignant), acute scrotum, and lymphoma of the testis.

---

### **Brian J. Flynn, MD**

*Director of Urogynecology, Reconstructive Urology and Urodynamics*

*Associate Professor of Surgery/Urology*

*University of Colorado Denver*

Brian J. Flynn, MD is the Director of Urogynecology, Reconstructive Urology and Urodynamics and associate professor at the University of Colorado. Dr Flynn received his BS in Electrical Engineering from the University of Rochester, Doctorate of Medicine from Temple University. He completed a residency in Urology at Geisinger Medical Center and his fellowship in Urogynecology and Reconstructive Urology at Duke University.

His primary areas of interest are Pelvic Reconstructive Surgery and Urogynecology. He is a national leader in the use of minimally invasive surgical techniques for the treatment of urinary incontinence in men and women and reinforced pelvic floor repairs in women. He has written updates for the AUA and has provided postgraduate instruction on the surgical management of post-prostatectomy incontinence, Management of complications of prolapse and incontinence surgery. He has authored numerous clinical papers, surgical videos, textbook chapters and has presented internationally on various topics including male and female urinary incontinence, pelvic organ prolapse, urinary diversion and urethral stricture disease.

---

### **Donald L. Lamm, MD**

*Director, Bladder Cancer-Genitourinary Oncology*

*Phoenix, Arizona*

After 28 years in academic practice Donald Lamm, MD, FACS, launched his private practice in Fall 2004. Dr Lamm graduated AOA from UCLA and did a rotating internship at the University of Oregon HSC in Portland. He practiced family medicine for two years as Director of the Colville Indian Health Service Clinic before returning to UCLA for a year of General Surgery and to UCSD for urology residency.

During his urology residency he developed an animal model for bladder cancer and found that Bacillus Calmette Guerin (the TB vaccine, BCG) inhibited tumor growth. After residency he and his family moved to San Antonio where Dr Lamm began his academic career as Assistant Professor of Surgery at the University of Texas Health Sciences Center. During his nine years in Texas he rose in rank to Professor and Acting Chairman of the Division of Urology. His VA and NIH research resulted in clinical studies that led to the FDA approval of BCG for bladder cancer.

*(continued...)*



## Faculty

*Donald L. Lamm, MD, (continued)*

Subsequent work by Dr Lamm, then Chairman of the Department of Urology at West Virginia University, demonstrated that BCG immunotherapy is superior to Adriamycin and Mitomycin C chemotherapy for superficial bladder cancer, significantly reducing the risk of bladder cancer progression to muscle invasion and metastasis. Dr Lamm's work is in part responsible for bladder cancer being one of only five cancers in the United States that has seen a reduced mortality despite an increased incidence. This reduction in mortality coincides with a reduction in the number of patients who lose their bladder as a result of radical cystoprostatectomy for muscle invasive or aggressive superficial disease.

Dr Lamm has authored over 270 peer-reviewed medical and scientific articles, and in addition to new treatments of bladder cancer, he has developed new approaches to the treatment of renal and prostate cancer as well. His primary interest, however, continues to be BCG therapy of bladder cancer.

---

### **M. Scott Lucia, MD**

*Associate Professor of Pathology*

*Director, Prostate Diagnostic Laboratory*

*Department of Pathology*

*University of Colorado Denver School of Medicine*

M. Scott Lucia, MD is Associate Professor and Chief of Genitourinary and Renal Pathology at the University of Colorado Denver and Health Sciences Center where he also serves as the Director of the Prostate Diagnostic Laboratory and Co-Director of the Prostate Cancer Research Laboratories. Dr Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT), sponsored by the Southwest Oncology Group, and the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK. He currently is the primary pathologist for the Vitamin E and Selenium Chemoprevention Trial (SELECT) also sponsored by the Southwest Oncology Group. Dr Lucia directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored over 70 peer-reviewed articles, reviews and book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, and mechanisms of carcinogenesis.

---

### **Paul D. Maroni, MD**

*Assistant Professor of Surgery (Urology)*

*University of Colorado Denver*

Dr Paul Maroni is fellowship-trained in Urologic Oncology. He has developed a busy practice in Urology and Urologic Oncology. Dr Maroni is extremely qualified in a broad scope of urologic surgery and in the areas of prostate, bladder, and kidney cancer and performs laparoscopic ("minimally invasive") as well as open procedures. He trained at the University of Illinois at Chicago College of Medicine, completed his residency at the University of Colorado Denver School of Medicine and completed his fellowship at Indiana University. He is a member/investigator of the Southwest Oncology Group.

Special areas of interest are minimally-invasive procedures for low-risk prostate cancer and surgery for advanced (high-risk) prostate cancer. He is an investigator in national trials for high-intensity focused  
*(continued...)*

## Faculty

*Paul D. Maroni, MD (continued)*

ultrasound (HIFU) treatments for prostate cancer and injection medications for the management of urinary symptoms related to benign prostate enlargement. He crafts treatment alternatives for patients based on individual values. In order to advance medical knowledge and improve patient outcomes, he will be actively recruiting patients to clinical trials for prostate cancer including active surveillance/watchful waiting (START trial), targeted therapies, and surgery for high-risk patients (PUNCH trial). He regularly participates in the genitourinary multidisciplinary second opinion conference.

Additionally, he has experience in specialized surgeries for the removal of metastatic masses in patients with advanced testicular cancer. He is happy to discuss complicated aspects of the management of testicular cancer and works closely with genitourinary medical oncologists to help treat this disease.

---

### **Mark A. Moyad, MD, MPH**

*Jenkins/Pokempner Director of Preventive and Alternative Medicine*

*Department of Urology*

*University of Michigan Medical Center*

Dr Moyad is the co-director of the men's health program at the University of Michigan. He received his master's degree in public health from the University of South Florida, where he was one of the lead investigators of the L-tryptophan dietary supplement study that helped to remove this dangerous supplement from the market. He published his first medical article in college on the relationship between a compound found in cottonseed oil and male infertility. Dr Moyad received his M.D. from Wayne State University School of Medicine. He is currently working part-time on his Ph.D. in pathology and N.D. (naturopathic doctor) degree. Dr Moyad is the author or co-author of four books and has three additional books coming out in the next 12 months, including a guide for men's and women's health and a breast cancer prevention book. He is the primary author of over 60 medical articles. Dr Moyad is the editor of the complementary/ preventive medicine medical book series from Humana Press. He has also been the guest editor of five different medical journals and reviews or edits articles for a number of medical journals, including: *Urology, Journal of Urology, Cancer, Nutrition and Cancer, British Journal of Urology*. Dr Moyad is the director of the complementary/preventive medicine course for the Annual American Urologic Association Meeting and the Annual Urologic Nurses Meeting. He has an endowed chair/directorship at the University of Michigan Medical Center in complementary and preventive medicine. Dr Moyad has had a consulting practice for almost 10 years, and he runs clinical trials and basic science studies in regards to complementary/preventive at the university and has lectured in all 50 states to health professionals and patients. He speaks internationally and gives courses in Europe and Asia on a regular basis. His latest research includes identifying the relationship between lipid changes and cancer risk and treatment.

## Sidebar header

---

### Jacob Rajfer, MD

*Professor of Urology*

*Chief of Urology, Harbor-UCLA Medical Center*

*David Geffen School of Medicine at UCLA*

Jacob Rajfer, MD is professor of urology at the University of California at Los Angeles (UCLA) and chief of urology at the Harbor-UCLA Medical Center in Torrance. Dr Rajfer received his medical degree from Northwestern University Medical School in Chicago, Illinois. He completed an internship in medicine at Los Angeles County - University of Southern California Medical Center and residencies in surgery at St. Joseph's Hospital, Denver, Colorado, and in urology at The Johns Hopkins Hospital, Baltimore, Maryland.

Dr Rajfer has focused his research on various aspects of erectile dysfunction (ED) and is currently investigating the effects of aging on the penile vascular system and how it relates to the rest of the vascular system, in general. In the early 1990s, he and his colleagues at UCLA discovered that nitric oxide (NO) was the actual chemical mediator of penile erection and that inhibition of phosphodiesterase (PDE) activity actually enhanced the erectogenic aspects of NO. In addition, his group showed that testosterone, and specifically dihydrotestosterone, was the active androgen necessary for the production of NO in the penis.

A frequent contributor to the medical literature, Dr Rajfer has published more than 200 journal articles and book chapters. His work has appeared in the *New England Journal of Medicine*, *JAMA*, *Cardiovascular Research*, *American Journal of Physiology*, *Neuroendocrinology*, *Urology*, and other journals.

Dr Rajfer is a member of numerous medical organizations, including the American Urological Association, American Society of Andrology, and the Sexual Medicine Society of North America. He is a fellow of the American College of Surgeons, an honorary fellow of the American Academy of Pediatrics, and a past president of the Los Angeles Urological Society.

---

### Matthew Rettig, MD

*Associate Professor of Hematology-Oncology*

*Co-Director, Prostate Cancer Program*

*Institute for Urologic Oncology*

*David Geffen School of Medicine at UCLA*

Matthew Rettig, MD is an Associate Professor in the Department of Medicine, Division of Hematology-Oncology, and the Department of Urology, and is the Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. After receiving his medical degree from Duke University, Dr Rettig completed internal medicine residency at the University of Washington before going to hematology-oncology fellowship at UCLA.

As a medical oncologist, he focuses on the management of genitourinary malignancies with a focused clinical emphasis on advanced prostate cancer. Dr Rettig has both a clinical and bench research program. He conducts multiple prostate cancer clinical trials that span the spectrum of the states of the disease: from neoadjuvant therapies to post-chemotherapy, castration-resistant disease. Dr Rettig's bench research program, which is funded by the NIH, Department of Defense and the Department of Veterans Affairs, is focused on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer and clear cell renal cell carcinoma.

## Faculty & Planner Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Grant/Downing Education is required to disclose to the participants any relevant financial relationships the staff, authors, faculty, or planning committee members have with commercial interests whose products or health care services will be discussed in their presentations. It is Grant/Downing Education's policy to ensure that all continuing medical education activities are planned independent from commercial companies and are free from commercial bias. The following disclosures of financial relationships represent all people who were involved with the development or delivery of the content of this educational activity.

### **David C. Beyer, MD, FACR, FACRO, FASTRO, Faculty**

David C. Beyer, MD, FACR, FACRO, FASTRO has reported that he has no relevant financial relationships.

### **Leslie Cohan, Planner**

Leslie Cohan has reported that she has no relevant financial relationships.

### **E. David Crawford, MD, Course Director/Faculty**

**Grant Research Support:** Endocare, Oncura/Galil/Eigen, Bostwick, Gen-Probe, Aeterna Zentaris, EDAP - HIFU, Ferring Pharmaceuticals, NIH/NCI, Cancer Center

**Advisory/Speakers' Bureau:** sanofi-aventis, Poniard, AstraZeneca, Glaxo Smith Kline, Ferring Pharmaceuticals, Endo Pharmaceuticals, Soar BioDynamics

### **Robert E. Donohue, MD, Faculty**

Robert E. Donohue, MD has reported that he has no relevant financial relationships.

### **Brian J. Flynn, MD, Faculty**

**Advisory/Review/Board Membership:** Ethicon, AMS

### **Donald L. Lamm, MD, Faculty**

**Speakers' Bureau:** Sanofi-Pasteur

**Advisory/Review/Board Membership:** Sanofi-Pasteur

### **M. Scott Lucia, MD, Faculty**

**Advisory/Review/Board Membership:** Glaxo Smith Kline, Gen-Probe, Veridex

### **Paul D. Maroni, MD, Faculty**

**Advisory/Review/Board Membership:** sanofi-aventis, EDAP Technomed

### **James McKiernan, MD, Reviewer**

**Speakers' Bureau:** sanofi-aventis

### **Mark A. Moyad, MD, MPH, Faculty**

**Speakers' Bureau:** Abbott Laboratories

**Advisory/Review/Board Membership:** Guthy Renker, NBT4, Farr Labs, Abbott Laboratories, Embria

### **Jacob Rajfer, MD, Faculty**

**Speakers' Bureau:** sanofi-aventis

### **Matthew Rettig, MD, Faculty**

**Speakers' Bureau:** sanofi-aventis

## Agenda

### Wednesday, November 4

6:00 – 8:00 pm Registration

### Thursday, November 5

7:00 – 7:55 am Registration and Continental Breakfast in Exhibit Hall

7:55 – 8:00 am Welcome and Introduction  
~ *E. David Crawford, MD*

#### Robotic Surgery

8:00 – 8:30 am The Role of Robotics in Urologic Surgery  
~ *Paul D. Maroni, MD*

8:30 – 9:00 am Point-Counterpoint: Prostate Cancer  
  
Robotic Surgery is Hype ~ *E. David Crawford, MD*  
Robotic Surgery is the Mainstream ~ *Paul D. Maroni, MD*

9:00 – 9:10 am Questions & Answers

#### Renal Cell Carcinoma

9:10 – 9:30 am Histologic Subtypes of Renal Cell Carcinoma  
~ *M. Scott Lucia, MD*

9:30 – 9:55 am Point-Counterpoint: Small Renal Masses  
  
Best to Remove ~ *Paul D. Maroni, MD*  
Best to Watch ~ *Donald L. Lamm, MD*

9:55 – 10:00 am Questions & Answers

10:00 – 10:15 am Break in Exhibit Hall

#### Female Urology, Part I

10:15 – 11:15 am Female Urology “Potpourri”  
~ *Brian J. Flynn, MD*

11:15 – 11:25 am Questions & Answers

#### Clinical Challenges

11:25 – Noon Case Presentations and Discussion

Noon Adjourn for the day

**Agenda**      **Friday, November 6**

7:00 – 8:00 am      Breakfast and Industry-Supported Satellite Symposium  
 The Evolving Role of Hormonal Therapy in the Management  
 of Prostate Cancer

**Bladder Cancer**

8:00 – 8:45 am      A Case-based Approach to the Management of Bladder Cancer  
 ~ Moderator: Robert Donohue, MD

Panel:      David C. Beyer, MD • E. David Crawford, MD  
 Donald L. Lamm, MD • Paul D. Maroni, MD

8:45 – 9:00 am      Questions & Answers

9:00 – 9:30 am      Non-muscle Invasive Bladder Cancer, including Chemoprevention ~  
 Review of Existing Guidelines & International Recommendations  
 ~ Donald L. Lamm, MD

9:30 – 9:55 am      Point-Counterpoint: Radiation & Bladder Cancer  
  
 Radiation Has No Role in the Treatment of Any Stage of Bladder Cancer  
 ~ Robert E. Donohue, MD  
 Radiation Plays a Major Role in Certain Stages of Bladder Cancer  
 ~ David C. Beyer, MD

9:55 – 10:00 am      Questions & Answers

10:00 – 10:15 am      Break in Exhibit Hall

10:15 – 10:35 am      What the Community Urologist Needs to Know About BCG  
 ~ Donald L. Lamm, MD

10:35 – 10:45 am      Questions & Answers

**Female Urology, Part II**

10:45 – 11:15 am      The Spectrum of Stress Incontinence Surgery, 2009  
 ~ Brian J. Flynn, MD

11:15 – 11:25 am      Questions & Answers

**Clinical Challenges**

11:25 – Noon      Case Presentations and Discussion

Noon – 1:00 pm      Lunch (provided)

**Agenda**    **Friday, November 6** (continued)**Prostate Cancer**

1:00 – 1:20 pm	<b>Challenges in Prostate Cancer: Why We Are 15 Years Behind Breast Cancer</b> ~ <i>David C. Beyer, MD</i>
1:20 – 1:50 pm	<b>Clinical and Pathologic Characteristics of Prostate Cancer (including new markers such as PCA3)</b> ~ <i>M. Scott Lucia, MD</i>
1:50 – 2:10 pm	<b>Chemoprevention Strategies</b> ~ <i>M. Scott Lucia, MD</i>
2:10 – 2:40 pm	<b>Point-Counterpoint:</b>  <b>Early Detection of Prostate Cancer Is Not Valuable In a Lot of Men</b> ~ <i>E. David Crawford, MD</i>  <b>We Can't Go Backwards – Of Course Screening Has Saved Lives</b> ~ <i>Robert E. Donohue, MD</i>
2:40 – 2:50 pm	<b>Questions &amp; Answers</b>
2:50 – 3:00 pm	<b>Break in Exhibit Hall</b>
3:00 – 3:20 pm	<b>What's New in Advanced Disease (CRPC)?</b> ~ <i>Matthew Rettig, MD</i>
3:20 – 3:50 pm	<b>An Update on Radiation Therapy for Prostate Cancer</b> ~ <i>David C. Beyer, MD</i>
3:50 – 4:00 pm	<b>Questions &amp; Answers</b>
4:00 pm	<b>Adjourn for the day</b>

**Agenda**

**Saturday, November 7**

7:15 – 8:00 am	Continental Breakfast
8:00 – 8:20 am	Chemotherapy for Urological Cancers ~ <i>Matthew Rettig, MD</i>
8:20 – 8:25 am	Questions & Answers
<b>Prostate Conditions</b>	
8:25 – 8:55 am	Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP ~ <i>E. David Crawford, MD</i>
8:55 – 9:25 am	Point-Counterpoint  Are We Ignoring Level One Evidence by Not Prescribing Appropriate Medical Therapy? ~ <i>E. David Crawford, MD</i> Alternative Medicine Should Be the Choice ~ <i>Mark A. Moyad, MD, MPH</i>
9:25 – 9:35 am	Questions & Answers
<b>Hypogonadism</b>	
9:35 – 10:05 am	Increasing Awareness, Diagnosis, and Treatment of Hypogonadism ~ <i>Jacob Rajfer, MD</i>
10:05 – 10:35 am	Point-Counterpoint: Late Onset Hypogonadism (LOH)  We are Under-diagnosing and Treating Men with LOH ~ <i>Jacob Rajfer, MD</i> LOH is a Non-existent Disease ~ <i>Robert E. Donohue, MD</i>
10:35 – 10:45 am	Questions & Answers
10:45 – 10:55 am	Break in Exhibit Hall
<b>Complementary Alternative Medicine</b>	
10:55 – 11:55 am	Fad Diets and Dietary Supplements for Urology Patients: What Works and What's Worthless ~ <i>Mark A. Moyad, MD, MPH</i>
11:55 – 12:10 pm	Pills and Tests: What Should I (the urologist) Be Taking and Getting? ~ <i>Mark A. Moyad, MD, MPH</i>
12:10 – 12:30 pm	Point-Counterpoint:  Why Every Man Should Be Offered Chemoprevention for Prostate Cancer ~ <i>E. David Crawford, MD</i> Chemoprevention Is Not for Every Man ~ <i>Mark A. Moyad, MD, MPH</i>
12:30 – 12:45 pm	Questions & Answers
12:45 pm	Meeting Adjourns





